Information Provided By: 
Fly News Breaks for January 14, 2020
MOR, INCY
Jan 14, 2020 | 06:33 EDT
JMP Securities analyst Reni Benjamin raised his price target on Incyte (INCY) to $121 and kept his Outperform rating after the company announced a global collaboration and license agreement for tafasitamab with MorphoSys (MOR) yesterday. Despite the $900M cash payment upon closing by Incyte, the analyst believes that the deal is net-positive for both companies as Incyte gains a "significant" mid-to-long term revenue driver while MorphoSys gets access to its established "hematology/oncology network and expertise."
News For INCY;MOR From the Last 2 Days
INCY
Apr 25, 2024 | 09:27 EDT
